Home | Welcome to Contract Pharma   
Last Updated Saturday, October 25 2014
Print

Financial Report: Gilead



Published July 24, 2014
Gilead

2Q Revenues: $6.5 billion (+136%)

2Q Earnings: $3.7 billion (+375%)

YTD Revenues: $11.5 billion (+118%)

YTD Earnings: $5.9 billion (+295%)

Comments: Antiviral product sales increased to $6.0 billion in the quarter driven by sales of Sovaldi, which launched in December 2013. Complera/Eviplera sales were $299.5 million, up 59%, and Stribild sales were $269.5 million, up 171%. Atripla sales declined 7% to $870.7 million and Truvada sales were flat in the quarter. Cardiovascular product sales increased to $266.7 million, up 14% with Letairis sales of $144.7 million, and Ranexa sales of $122.0 million.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On